Altimmune(US:ALT) Prnewswireยท2025-08-21 15:06Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague on behalf of investors who acquired the company's securities during the specified class period from August 10, 2023, to June 25, 2025 [1][2]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from its IMPACT Phase 2b trial of Pemvidutide for MASH treatment, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3]. Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted by 53.2% in one day, dropping from a closing price of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4].